{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T13:33:03Z","timestamp":1765805583214,"version":"3.30.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3165,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,1]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>\n                                 <jats:bold>The effectiveness of HCV antiviral therapy in patients who have undergone recent drug dependency treatment and continue to inject drugs sporadically is presently not clear. Patients attending a community-based drug rehabilitation and naltrexone implant clinic from October 2002 until March 2005 were screened for HCV infection and if positive offered further assessment and treatment with interferon and ribavirin therapy. The first 50 patients to commence HCV therapy and complete at least 6 months follow-up were prospectively studied. ETR response (HCV PCR negative) was 34\/50 (68%) and SVR 6 months post-treatment was 31\/50 (62%). Viral eradication was maintained in those 22 patients that have had 12 months or more post-treatment follow-up. Eleven (22%) patients stopped therapy early due to side effects or poor compliance. Only two patients with an ETR likely reinfected due to unsafe injection practices. One was re-treated and achieved an SVR. Of the patients achieving a 6-month SVR, 17 of 31 patients reported no further IDU and 13 of 31 patients occasional IDU during treatment and this was maintained after HCV treatment cessation. 46% of patients received antidepressant and\/or antipsychotic medication during treatment.<\/jats:bold>\n                                 <jats:bold>\n                                    Conclusion:\n                                 <\/jats:bold>\n                                 <jats:bold>This study of HCV treatment in a community-based subcutaneous naltrexone implant clinic found antiviral therapy resulted in a 62% SVR. This result is comparable to that reported in hospital-based clinics in non-IDU patients. The side effect profile and compliance was also similar. HCV antiviral therapy should be offered to this large and currently under treated group. (Hepatology 2007;45:111\u2013117.)<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.21470","type":"journal-article","created":{"date-parts":[[2006,12,22]],"date-time":"2006-12-22T23:21:04Z","timestamp":1166829664000},"page":"111-117","update-policy":"http:\/\/dx.doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":47,"title":["Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants"],"prefix":"10.1097","volume":"45","author":[{"given":"Gary P.","family":"Jeffrey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerry","family":"MacQuillan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fern","family":"Chua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam","family":"Galhenage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Bull","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Hulse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"O'Neil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-16-20241202","first-page":"25","article-title":"Hepatitis C epidemiology.","volume":"242","author":"Thomas","year":"2000","journal-title":"Curr Top Microbiol Immunol"},{"key":"R2-16-20241202","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1053\/jlts.2003.50063","article-title":"Liver transplantation for HCV associated liver cirrhosis: Recipient predictors of outcomes in a population with significant genotype 3 and 4 distribution.","volume":"9","author":"Zekry","year":"2003","journal-title":"Liver Transplant"},{"key":"R3-16-20241202","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.jhep.2004.12.031","article-title":"Estimating the impact of hepatitis C virus therapy on future liverrelated morbidity, mortality and costs related to chronic hepatitis C.","volume":"42","author":"Buti","year":"2005","journal-title":"J Hepatol"},{"key":"R4-16-20241202","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1086\/345554","article-title":"Hepatitis C virus seroconversion among young injection drug users: relationships and risks.","volume":"186","author":"Hahn","year":"2002","journal-title":"J Infect Dis"},{"key":"R5-16-20241202","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/09595239800187451","article-title":"Injecting nation: achieving control of hepatitis C in Australia.","volume":"16","author":"Wodak","year":"1997","journal-title":"Drug Alcohol Rev"},{"key":"R6-16-20241202","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa2b plus ribavirin compared with interferon alfa2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"R7-16-20241202","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alpha2a plus ribavirin for chronic hepatitis C virus infection.","volume":"347","author":"Fried","year":"2002","journal-title":"N Eng J Med"},{"key":"R9-16-20241202","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/hep.20119","article-title":"Diagnosis, management, and treatment of hepatitis C.","volume":"39","author":"Strader","year":"2004","journal-title":"HEPATOLOGY"},{"key":"R10-16-20241202","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/j.1360-0443.2004.00821.x","article-title":"Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules?","volume":"99","author":"Schaefer","year":"2004","journal-title":"Addiction"},{"key":"R11-16-20241202","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1053\/jhep.2001.25882","article-title":"Treatment of hepatitis C infection in injection drug users.","volume":"34","author":"Backmund","year":"2001","journal-title":"HEPATOLOGY"},{"key":"R12-16-20241202","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/jhep.2003.50031","article-title":"Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups.","volume":"37","author":"Schaefer","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R13-16-20241202","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1111\/j.1572-0241.2003.07702.x","article-title":"Response ot treatment of hepatitis C in individuals with a recent history of intravenous drug abuse.","volume":"98","author":"Van Thiel","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"R14-16-20241202","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jsat.2005.06.002","article-title":"The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone.","volume":"29","author":"Sylvestre","year":"2005","journal-title":"J Subst Abuse Treat"},{"key":"R15-16-20241202","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1046\/j.1445-5994.2003.00410.x","article-title":"Outcome, tolerability and compliance of compassionate use interferon and ribavirin for hepatitis C infection in a shared care hospital clinic.","volume":"33","author":"Kontorinis","year":"2003","journal-title":"Intern Med J"},{"key":"R17-16-20241202","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3109\/10826089509048753","article-title":"Methadone maintenance and the likelihood of risky needlesharing.","volume":"30","author":"Caplehorn","year":"1995","journal-title":"Int J Addict"},{"key":"R18-16-20241202","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/02791072.2000.10400238","article-title":"Addiction pharmacotherapy 2000: new options, new challenges.","volume":"32","author":"Rawson","year":"2003","journal-title":"J of Pscychoactive Drugs"},{"key":"R19-16-20241202","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0140-6736(98)05356-2","article-title":"Role of maintenance treatment in opioid dependence.","volume":"353","author":"Ward","year":"1999","journal-title":"Lancet"},{"key":"R20-16-20241202","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/13556210410001674103","article-title":"Blood naltrexone and 6naltrexol levels following naltrexone implant: comparing rwo naltrexone imlplants.","volume":"9","author":"Hulse","year":"2004","journal-title":"Addict Biol"},{"key":"R21-16-20241202","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1177\/0310057X0303100211","article-title":"Use of oral and implantable naltrexone in the management of the opioid impaired physician.","volume":"31","author":"Hulse","year":"2003","journal-title":"Anaesth Intensive Care"},{"key":"R22-16-20241202","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ijgo.2003.10.001","article-title":"Methadone maintenance vs. implantable naltrexone treatment in the pregnant heroin user.","volume":"85","author":"Hulse","year":"2004","journal-title":"International J of Gyn Obst"},{"key":"R23-16-20241202","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1053\/gast.2002.35950","article-title":"Adherence to combination therapy enhances sustained response in genotype1infected patients with chronic hepatitis C.","volume":"123","author":"McHutchison","year":"2002","journal-title":"Gastroenterology"},{"key":"R24-16-20241202","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1053\/j.gastro.2006.01.034","article-title":"Peginterferon alfa2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response.","volume":"130","author":"Kamal","year":"2006","journal-title":"Gastroenterology"},{"key":"R25-16-20241202","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1365-2036.2005.02631.x","article-title":"The impact of past alcohol use on treatment response rates in patients with chronic hepatitis C.","volume":"22","author":"Chang","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"R26-16-20241202","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1046\/j.1365-2893.2002.00360.x","article-title":"Alcohol abstinence does not offset the strong negative effect of lifetime alcohol consumption on the outcome of interferon therapy.","volume":"9","author":"Tabone","year":"2002","journal-title":"J Viral Hepat"},{"key":"R27-16-20241202","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1053\/j.gastro.2006.02.023","article-title":"Alcohol use and treatment of hepatitis C virus: results of a national multicentre study.","volume":"130","author":"Anand","year":"2006","journal-title":"Gastroenterology"},{"key":"R28-16-20241202","first-page":"322","article-title":"Effect of morphine, hydromorphone, methadone, mescaline, trypan blue, vitamin A, sodium salicylate, and caffeine on the serum interferon level in response to viral infection.","volume":"214","author":"Geber","year":"1975","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"R29-16-20241202","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0002-9440(10)63476-1","article-title":"Morphine enhances hepatitis C virus (HCV) replicon expression.","volume":"163","author":"Li","year":"2003","journal-title":"Am J Pathol"},{"key":"R30-16-20241202","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/01.mjt.0000132250.95650.85","article-title":"Opioid therapy and immunosupression: a review.","volume":"11","author":"Vallejo","year":"2004","journal-title":"Am J Ther"},{"key":"R31-16-20241202","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/jurban\/jth114","article-title":"Screening for depressive symptoms among HCVinfected injection drug users: examination of the utility of the CESD and the Beck Depression Inventory.","volume":"81","author":"Golub","year":"2004","journal-title":"J Urban Health"},{"key":"R32-16-20241202","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000049487","article-title":"Treatment of chronic hepatitis C in injecting drug users: 5 years followup.","volume":"8","author":"Dalgard","year":"2002","journal-title":"Eur Addict Res"},{"key":"R33-16-20241202","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/S0140-6736(02)08435-0","article-title":"Protection against persistence of hepatitis C.","volume":"359","author":"Mehta","year":"2002","journal-title":"Lancet"},{"key":"R34-16-20241202","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1136\/gut.52.6.900","article-title":"Second infection with a different hepatitis C virus genotype in a intravenous drug user during interferon therapy.","volume":"52","author":"Asselah","year":"2003","journal-title":"Gut"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.21470","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200701000-00016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T16:07:41Z","timestamp":1733155661000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200701000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.21470","relation":{},"ISSN":["0270-9139"],"issn-type":[{"type":"print","value":"0270-9139"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}